A Phase 2 interventional study of ARGX-117 and Placebo in Multifocal Motor Neuropathy, sponsored by argenx. Completed at 40 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and efficacy of 2 dose regimens of ARGX-117 versus placebo, in participants with MMN previously stabilized with IVIg (intravenous immunoglobulin).
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of unless resolved by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of the IMP. Participants with the following carcinomas will be eligible:
Prior/concomitant therapy
Positive serum test at screening for an active viral infection with any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous administration of ARGX-117
Biological: ARGX-117
Intravenous administration of placebo
Other: Placebo
Intravenous administration of ARGX-117
Intravenous administration of placebo
Number of Participants With AEs and SAEs
AE : Adverse Events, SAE: Serious Adverse Events
Time frame: Up to 80 weeks
Time to the First Retreatment With IVIg
The time to first retreatment with intravenous immunoglobulin (IVIg) is defined as the time from the last IVIg administration before randomization until the first IVIg retreatment during the 16-week treatment period
Time frame: Up to 16 weeks
Time-to-relapse
Time-to-relapse is defined as the time from randomization until a participant met the threshold for clinically meaningful deterioration
Time frame: Up to 16 weeks
iAUC of the Change From Baseline in mMRC-10 Sum Score
The Modified Medical Research Council (mMRC)-10 sum score assesses muscle strength of 10 muscles groups, both sides (left and right). A score between 0 (paralysis) and 5 (normal strength) is assigned for each muscle group. A higher value indicates better muscle strength. The total score, ranging from 0 to 100, is based on the sum of both the left and right side of the body. The Incremental Area Under Curve (iAUC) is the area under the curve of the change from baseline in the Modified Medical Research Council (mMRC)-10 score. A positive AUC indicates a favorable outcome while a negative AUC indicates an unfavorable outcome.
Time frame: Up to 16 weeks
Change From Baseline in the Average Score of the 2 Most Important Muscle Groups as Assessed by the mMRC-14 Sum Score
The Modified Medical Research Council (mMRC)-14 assesses muscle strength of 14 muscles groups, both sides (left and right). A score between 0 and 5 (normal strength) is assigned. This endpoint is the change from baseline in the average score of the 2 most important muscle groups affected by the disease. It ranges between 0 and 5. A change of more than 0 represents an improvement in strength, and a change less than 0 represents worsening.
Time frame: At week 16
Change From Baseline in the mMRC-14 Sum Score
The Modified Medical Research Council (mMRC)-14 scores range from 0 to 140 with a higher score representing better muscle strength. A change of more than 0 represents an improvement in strength, and a change less than 0 represents worsening.
Time frame: At week 16
Proportion of Participants Showing a Deterioration of at Least 2 Points as Assessed by the mMRC-10 Sum Score
The Modified Medical Research Council (mMRC)-10 scores evaluates motor strength/weakness from 10 predetermined muscle groups. A higher proportion of participants showing a deterioration represents a worsening of the outcome.
Time frame: Up to 16 weeks
iAUC of the Change From Baseline in GS Daily Average
Measurement of grip strength (GS) has been done using the Martin vigorimeter in kPa. The incremental Area Under Curve (iAUC) is the area under the curve of the change from baseline of GS daily average. The 3 daily measurements of GS from the left hand and the 3 daily measurements of GS from the right hand have been recorded and the daily average for the left hand and right hand has been calculated, respectively.
Time frame: Up to 16 weeks
Percent Change From Baseline in GS 3-day Moving Average
Measurement of grip strength (GS) has been done using the Martin vigorimeter in kPa. The 3 daily measurements of GS from the left hand and the 3 daily measurements of GS from the right hand have been recorded and the daily average for the left hand and right hand has been calculated, respectively. A 3-day moving average has been generated based on the average over the last 3 days of the obtained daily averages for each hand.
Time frame: At week 16
Change From Baseline in the MMN-RODS Centile Score
The Rasch-built Overall Disability Scale for MMN (MMN-RODS) is a disease-specific PRO instrument constructed to capture activity limitations in patients with MMN. Raw sum scores of the 25-item MMN-RODS (range, 0-50) were converted to a centile metric score ranging from 0 to 100. Lower scores indicated a greater degree of disability.
Time frame: At week 16
Percent Change From Baseline in the Average Time for Upper Extremity (Arm and Hand) Function
The 9-Hole Peg Test (9-HPT) results are based on the time to complete the assessment with a shorter time representing better muscle strength. A change of less than 0 represents an improvement in strength, and a change more than 0 represents worsening.
Time frame: At week 16
Proportion of Participants by Level of Severity on Each Dimension of the EQ-5D-5L Scale
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale includes five dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is ranked with a level 1-5 with level 1 being no problems and level 5 representing extreme problems.
Time frame: At week 16
Change From Baseline in Quality of Life Using EQ-5D-5L Visual Analog Scale
The EQ-5D-5L visual analog scale is from 0-100 with 0 representing the worst health. A change of more than 0 represents an improvement in health, and a change of less than 0 represents worsening.
Time frame: At week 16
Change From Baseline in the CAP-PRI
The Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI) assesses disease-specific quality of life. This instrument includes the assessment of 15 items yielding a total score ranging from 0 to 30. A change of less than 0 represents an improvement in health, and a change more than 0 represents worsening.
Time frame: At week 16
Proportion of Participants by Level of Improvement Using the PGI-C Scale
Patient Global Impression of Change (PGI-C) scale ranks a patients condition from 1-7 with 1 representing the most improvement and 7 representing the most decline in their condition.
Time frame: Up to 16 weeks
Change From Baseline in the 9-item FSS Average Total Score
9-item Fatigue Severity Scale (FSS) average score is the sum of the 9 items divided by the number of items. It ranges from 0 to 7 a higher score representing more severe fatigue. A change of less than 0 indicates an improvement.
Time frame: Up to 16 weeks
Percent of Total Hours for Work-related and Household Chore Activities Lost, as Part of the HRPQ
The Health-Related Productivity Questionnaire (HRPQ) provides data related to missed hours at work or educational activities and reduced effectiveness during any attempted work.
Time frame: Up to 16 weeks
Change From Baseline in Effectiveness, Side Effects, Convenience, and Overall Satisfaction Scores as Assessed by the TSQM-14
Each Treatment Satisfaction Questionnaire for Medication-14 items (TSQM-14) domain score ranges from 0-100 with higher scores representing greater satisfaction with the treatment. A change greater than 0 indicates an improvement in satisfaction.
Time frame: Up to 16 weeks
Maximum Empasiprubart Serum Concentrations (Cmax)
Time frame: Up to 16 weeks
Percent Change From Baseline in Free C2, Total C2, and Functional Complement Activity (CH50)
Time frame: At week 16
Incidence of Antidrug Antibodies (ADA) Against Empasiprubart
Time frame: Up to 16 weeks
| Milestone | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Started | 18 | 9 | 18 | 9 |
| Completed | 17 | 8 | 18 | 9 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
AE : Adverse Events, SAE: Serious Adverse Events
| Participants | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Number of Participants with a AE | 14 | 5 | 14 | 6 |
| Number of Participants with a Treatment-related AE | 7 | 0 | 2 | 2 |
| Number of Participants with a SAE | 2 | 0 | 0 | 0 |
| Number of Participants with a Treatment-related SAE | 1 | 0 | 0 | 0 |
The time to first retreatment with intravenous immunoglobulin (IVIg) is defined as the time from the last IVIg administration before randomization until the first IVIg retreatment during the 16-week treatment period
| days | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Time to the First Retreatment With IVIg | NA | 37 (16.0 to —) | NA | NA |
Time-to-relapse is defined as the time from randomization until a participant met the threshold for clinically meaningful deterioration
| days | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Time-to-relapse | NA (17.0 to —) | 26 (7.0 to —) | NA (70.0 to —) | 28.0 (7.0 to 99.0) |
The Modified Medical Research Council (mMRC)-10 sum score assesses muscle strength of 10 muscles groups, both sides (left and right). A score between 0 (paralysis) and 5 (normal strength) is assigned for each muscle group. A higher value indicates better muscle strength. The total score, ranging from 0 to 100, is based on the sum of both the left and right side of the body. The Incremental Area Under Curve (iAUC) is the area under the curve of the change from baseline in the Modified Medical Research Council (mMRC)-10 score. A positive AUC indicates a favorable outcome while a negative AUC indicates an unfavorable outcome.
| mMRC score*weeks | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| iAUC of the Change From Baseline in mMRC-10 Sum Score | 110.25 (-32.25 to 228.75) | -182.50 (-362.50 to 130.50) | 283.75 (-17.50 to 432.00) | -93.50 (-158.50 to -13.00) |
The Modified Medical Research Council (mMRC)-14 assesses muscle strength of 14 muscles groups, both sides (left and right). A score between 0 and 5 (normal strength) is assigned. This endpoint is the change from baseline in the average score of the 2 most important muscle groups affected by the disease. It ranges between 0 and 5. A change of more than 0 represents an improvement in strength, and a change less than 0 represents worsening.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Change From Baseline in the Average Score of the 2 Most Important Muscle Groups as Assessed by the mMRC-14 Sum Score | 0.50 (0.50 to 0.50) | 0.00 (0.00 to 0.50) | 0.50 (0.00 to 1.00) | 0.00 (0.00 to 0.50) |
The Modified Medical Research Council (mMRC)-14 scores range from 0 to 140 with a higher score representing better muscle strength. A change of more than 0 represents an improvement in strength, and a change less than 0 represents worsening.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Change From Baseline in the mMRC-14 Sum Score | 4.0 (2.0 to 8.0) | 0.0 (-8.0 to 0.0) | 7.0 (1.0 to 11.0) | 1.0 (-2.0 to 8.0) |
The Modified Medical Research Council (mMRC)-10 scores evaluates motor strength/weakness from 10 predetermined muscle groups. A higher proportion of participants showing a deterioration represents a worsening of the outcome.
| Participants | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Proportion of Participants Showing a Deterioration of at Least 2 Points as Assessed by the mMRC-10 Sum Score | 1 | 4 | 2 | 2 |
Measurement of grip strength (GS) has been done using the Martin vigorimeter in kPa. The incremental Area Under Curve (iAUC) is the area under the curve of the change from baseline of GS daily average. The 3 daily measurements of GS from the left hand and the 3 daily measurements of GS from the right hand have been recorded and the daily average for the left hand and right hand has been calculated, respectively.
| kPa*weeks | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Most Affected Hand | 508.25 (237.17 to 1788.08) | -63.75 (-591.42 to 671.08) | 1269.67 (289.00 to 3139.17) | 1.67 (-267.67 to 124.00) |
| Least Affected Hand | 356.08 (-57.17 to 1372.42) | -363.17 (-975.67 to 655.50) | 554.00 (111.00 to 2847.00) | -100.33 (-291.00 to 478.50) |
Measurement of grip strength (GS) has been done using the Martin vigorimeter in kPa. The 3 daily measurements of GS from the left hand and the 3 daily measurements of GS from the right hand have been recorded and the daily average for the left hand and right hand has been calculated, respectively. A 3-day moving average has been generated based on the average over the last 3 days of the obtained daily averages for each hand.
| Percent change | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Most Affected Hand | 31.88 (0.00 to 53.91) | 1.63 (-1.96 to 10.42) | 61.48 (8.12 to 101.10) | 3.68 (-3.64 to 16.67) |
| Least Affected Hand | 13.13 (0.25 to 37.68) | 5.69 (-0.52 to 7.07) | 17.97 (6.43 to 69.38) | 4.90 (1.61 to 7.69) |
The Rasch-built Overall Disability Scale for MMN (MMN-RODS) is a disease-specific PRO instrument constructed to capture activity limitations in patients with MMN. Raw sum scores of the 25-item MMN-RODS (range, 0-50) were converted to a centile metric score ranging from 0 to 100. Lower scores indicated a greater degree of disability.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Change From Baseline in the MMN-RODS Centile Score | 6.0 (0.0 to 14.0) | 0.0 (-2.0 to 0.0) | 7.5 (0.0 to 17.0) | 0.0 (-5.0 to 1.0) |
The 9-Hole Peg Test (9-HPT) results are based on the time to complete the assessment with a shorter time representing better muscle strength. A change of less than 0 represents an improvement in strength, and a change more than 0 represents worsening.
| Percent change | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Dominant Hand | -10.760 (-41.463 to -1.250) | -5.691 (-16.049 to 9.254) | -8.571 (-20.907 to 0.000) | -12.150 (-16.212 to 2.500) |
| Non-Dominant Hand | -5.236 (-23.529 to 6.343) | -3.394 (-20.690 to 5.000) | -14.286 (-25.714 to -8.725) | -1.402 (-7.368 to 4.762) |
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale includes five dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is ranked with a level 1-5 with level 1 being no problems and level 5 representing extreme problems.
| Participants | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Mobility — 1 - No Problem | 9 | 3 | 11 | 2 |
| Mobility — 2 - Slight Problem | 2 | 3 | 2 | 6 |
| Mobility — 3 - Moderate Problem | 6 | 2 | 3 | 1 |
| Mobility — 4 - Severe Problem | 1 | 1 | 1 | 0 |
| Mobility — 5 - Unable to | 0 | 0 | 1 | 0 |
| Self-Care — 1 - No Problem | 5 | 3 | 8 | 3 |
| Self-Care — 2 - Slight Problem | 8 | 4 | 8 | 5 |
| Self-Care — 3 - Moderate Problem | 4 | 2 | 1 | 1 |
| Self-Care — 4 - Severe Problem | 1 | 0 | 0 | 0 |
| Self-Care — 5 - Unable to | 0 | 0 | 1 | 0 |
| Usual Activities — 1 - No Problem | 5 | 2 | 8 | 2 |
| Usual Activities — 2 - Slight Problem | 6 | 4 | 5 | 4 |
| Usual Activities — 3 - Moderate Problem | 6 | 2 | 4 | 3 |
| Usual Activities — 4 - Severe Problem | 1 | 1 | 0 | 0 |
| Usual Activities — 5 - Unable to | 0 | 0 | 1 | 0 |
| Pain/Discomfort — 1 - No Problem | 9 | 6 | 10 | 2 |
| Pain/Discomfort — 2 - Slight Problem | 5 | 1 | 5 | 5 |
| Pain/Discomfort — 3 - Moderate Problem | 3 | 2 | 2 | 2 |
| Pain/Discomfort — 4 - Severe Problem | 1 | 0 | 1 | 0 |
| Pain/Discomfort — 5 - Unable to | 0 | 0 | 0 | 0 |
| Anxiety/Depression — 1 - No Problem | 13 | 2 | 15 | 5 |
| Anxiety/Depression — 2 - Slight Problem | 4 | 6 | 1 | 2 |
| Anxiety/Depression — 3 - Moderate Problem | 1 | 1 | 2 | 2 |
| Anxiety/Depression — 4 - Severe Problem | 0 | 0 | 0 | 0 |
| Anxiety/Depression — 5 - Unable to | 0 | 0 | 0 | 0 |
The EQ-5D-5L visual analog scale is from 0-100 with 0 representing the worst health. A change of more than 0 represents an improvement in health, and a change of less than 0 represents worsening.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Change From Baseline in Quality of Life Using EQ-5D-5L Visual Analog Scale | 5.0 (0.0 to 13.0) | 7.0 (-8.0 to 10.0) | 6.0 (2.0 to 8.0) | -6.0 (-10.0 to 9.0) |
The Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI) assesses disease-specific quality of life. This instrument includes the assessment of 15 items yielding a total score ranging from 0 to 30. A change of less than 0 represents an improvement in health, and a change more than 0 represents worsening.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Change From Baseline in the CAP-PRI | -2.5 (-6.0 to -1.0) | 0.0 (-1.0 to 2.0) | -2.0 (-5.0 to -1.0) | 1.0 (-1.0 to 2.0) |
Patient Global Impression of Change (PGI-C) scale ranks a patients condition from 1-7 with 1 representing the most improvement and 7 representing the most decline in their condition.
| Participants | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| 1 - Very much improved | 7 | 0 | 4 | 0 |
| 2 - Much improved | 3 | 1 | 8 | 2 |
| 3 - Minimally improved | 7 | 0 | 3 | 2 |
| 4 - No change | 0 | 3 | 2 | 2 |
| 5 - Minimally worse | 1 | 2 | 0 | 2 |
| 6 - Much worse | 0 | 1 | 1 | 1 |
| 7 - Very much worse | 0 | 2 | 0 | 0 |
9-item Fatigue Severity Scale (FSS) average score is the sum of the 9 items divided by the number of items. It ranges from 0 to 7 a higher score representing more severe fatigue. A change of less than 0 indicates an improvement.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Change From Baseline in the 9-item FSS Average Total Score | -0.444 (-1.556 to 0.000) | 0.222 (0.111 to 1.222) | -0.111 (-0.556 to 0.111) | 0.222 (-0.222 to 1.000) |
The Health-Related Productivity Questionnaire (HRPQ) provides data related to missed hours at work or educational activities and reduced effectiveness during any attempted work.
| Percent | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Work Activities lost | 10.00 (0.00 to 15.00) | 36.00 (0.00 to 46.00) | 0.00 (0.00 to 12.13) | 24.17 (17.50 to 37.78) |
| Household Chore Activities lost | 33.33 (10.00 to 60.00) | 20.00 (12.50 to 64.50) | 15.00 (0.00 to 35.00) | 43.75 (27.62 to 60.00) |
Each Treatment Satisfaction Questionnaire for Medication-14 items (TSQM-14) domain score ranges from 0-100 with higher scores representing greater satisfaction with the treatment. A change greater than 0 indicates an improvement in satisfaction.
| score on a scale | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Effectiveness | 0.000 (-16.667 to 27.778) | -22.222 (-33.333 to -16.667) | 25.000 (0.000 to 38.889) | -11.111 (-16.667 to 5.556) |
| Side effects | 0.000 (0.000 to 18.750) | 0.000 (0.000 to 18.750) | 0.000 (0.000 to 0.000) | 0.000 (0.000 to 12.500) |
| Convenience | 5.556 (0.000 to 22.222) | 5.556 (0.000 to 5.556) | 5.556 (0.000 to 11.111) | -5.556 (-11.111 to 5.556) |
| Overall Satisfaction | 3.6 (-7.1 to 28.6) | -14.3 (-28.6 to -14.3) | 3.6 (0.0 to 28.6) | -14.3 (-21.4 to -7.1) |
| ug/mL | ARGX-117 Cohort 1 | ARGX-117 Cohort 2 |
|---|---|---|
| Day 1 | 777.1 ± 202.6 | 400.1 ± 73.4 |
| Day 8 | 590.8 ± 164.0 | 273.8 ± 88.1 |
| Day 15 | 672.3 ± 118.4 | 340.5 ± 59.0 |
| Day 22 | 802.3 ± 202.4 | 356.2 ± 42.3 |
| Day 29 | 725.2 ± 176.5 | 394.1 ± 60.6 |
| Day 43 | 797.3 ± 153.2 | — |
| Day 57 | 819.9 ± 187.6 | 391.6 ± 128.1 |
| Day 71 | 871.9 ± 183.4 | — |
| Day 85 | 876.3 ± 222.5 | 349.4 ± 71.1 |
| Day 99 | 891.8 ± 125.2 | — |
| Percent change | ARGX-117 Cohort 1 | ARGX-117 Cohort 2 | Total Placebo (Cohort 1 and 2 Combined) |
|---|---|---|---|
| Free C2 | -98.915 (-99.031 to -98.635) | -98.079 (-98.532 to -97.324) | -0.669 (-13.876 to 7.625) |
| Total C2 | 331.82 (314.29 to 475.34) | 296.34 (219.80 to 332.00) | 3.85 (-4.00 to 10.88) |
| CH50 | -89.01 (-95.68 to -83.92) | -64.33 (-69.00 to -45.27) | -1.50 (-13.04 to 9.71) |
| Participants | ARGX-117 Cohort 1 | ARGX-117 Cohort 2 | Total Placebo (Cohort 1 and 2 Combined) |
|---|---|---|---|
| Incidence of Antidrug Antibodies (ADA) Against Empasiprubart | 0 | 1 | 0 |
Collected over Up to 80 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARGX-117 Cohort 1 | 0/18 (0%) | 2/18 (11.1%) | 14/18 (77.8%) |
| Placebo Cohort 1 | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| ARGX-117 Cohort 2 | 0/18 (0%) | 0/18 (0%) | 14/18 (77.8%) |
| Placebo Cohort 2 | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Event | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/18 | 0/9 | 0/18 | 0/9 |
| PneumoniaInfections and infestations | 1/18 | 0/9 | 0/18 | 0/9 |
| Event | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/18 | 0/9 | 4/18 | 3/9 |
| HeadacheNervous system disorders | 5/18 | 1/9 | 5/18 | 2/9 |
| FatigueGeneral disorders | 0/18 | 0/9 | 2/18 | 2/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/18 | 0/9 | 3/18 | 0/9 |
| Urinary tract infectionInfections and infestations | 2/18 | 0/9 | 1/18 | 0/9 |
| Upper respiratory tract infectionInfections and infestations | 0/18 | 1/9 | 1/18 | 0/9 |
| Gastrointestinal infectionInfections and infestations | 0/18 | 1/9 | 0/18 | 0/9 |
| ParonychiaInfections and infestations | 0/18 | 1/9 | 0/18 | 0/9 |
| Sinusitis bacterialInfections and infestations | 0/18 | 0/9 | 0/18 | 1/9 |
| Oedema peripheralGeneral disorders | 0/18 | 1/9 | 1/18 | 0/9 |
| Age, Categorical(Participants) | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 7 | 16 | 7 | 46 |
| >=65 years | 2 | 2 | 2 | 2 | 8 |
| Age, Continuous(years) | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 | Total |
|---|---|---|---|---|---|
| Median | 54.5 (47.0 to 61.0) | 44.0 (42.0 to 54.0) | 55.5 (50.0 to 59.0) | 58.0 (55.0 to 61.0) | 55.0 (47.0 to 61.0) |
| Sex: Female, Male(Participants) | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 | Total |
|---|---|---|---|---|---|
| Female | 7 | 4 | 6 | 4 | 21 |
| Male | 11 | 5 | 12 | 5 | 33 |
| Race/Ethnicity, Customized(Participants) | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 | Total |
|---|---|---|---|---|---|
| White | 17 | 7 | 17 | 8 | 49 |
| Not Reported | 0 | 1 | 1 | 1 | 3 |
| Other | 1 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | ARGX-117 Cohort 1 | Placebo Cohort 1 | ARGX-117 Cohort 2 | Placebo Cohort 2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 17 | 8 | 16 | 7 | 48 |
| Not Reported | 1 | 0 | 1 | 2 | 4 |
| Unknown | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in Jun 2024, 26 months.
Results were first posted in May 2026, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empasiprubart